Navigation Links
Treatment of Sickle Cell Anemia Using Gene Therapy.

A research was conducted by Selda Samakoglu and colleagues at the Memorial Sloan-Kettering Cancer Center. This research opened new doors in the treatment of the genetic disease, Sickle cell anemia // . The treatment combines both gene therapy and RNA interference therapy. So far the treatment has worked well in the laboratory stage and will be of great success in curing the disorder.

Sickle cell disease is a genetic disease affecting 80,000 people in the US alone. The Red Blood Cells (RBCs) become lose there normal disk shape and become sickle shaped. Due to this abnormality there is hindrance in the movement of these sickled RBC. The movement inside the small blood vessels is restricted and this results in piling, clumping inside the vessels. This eventually blocks the vessels leading to stroke, pain, infection and organ damage.

This disease is very much prevalent among the Africans, Mediterranean, Indian or Middle Eastern individuals. At present the treatment is that the affected people are given a stem cell transplant from a donor. It is very difficult to find an exact mach and less than 20% of the children suffering from the diseases find a complete donor match.

The researchers said that at the moment they are working with animal model (mice) and after the tests results prove to be positive they will start human trails and bring about the treatment procedure in the main stream of medicine within a few years.

The stem cells taken from the bone marrow are cultured in the lab and a small RNA sequence that interferes with the production of beta S-globin is integrated. This is because this sequence that produces beta S-globin is altered in these patients hence the altered gene is prevented from getting translated to proteins. This set up is then inserted in a gene that promotes production of healthy hemoglobin chains.

The net result is the production of a transgene which is then inserted into a vector (virus) and i s introduced into cell cultures. This virus is then taken into the stem cells of the sickle cell patients. After that the cells don’t produce beta S-globin but functions like the normal healthy Red Blood Cells. Further studies will be conducted even on the genetic disease Thalassemia which will be very useful in conducting human trials and studying the results of their sickle cell therapy.

The medical community appreciated the research and said the faster the cure more the lives will be saved. At present 1000 children are suffering from the disease and it would save their lives.

But they also warned that genetic therapy has its own disadvantages and complications similar to the various gene therapies. All of it has to be foreseen and eliminated for a safe procedure without any side effects to tackle sickle cell anemia.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... The schedule ... in this country. The AutismOne 2016 Conference, which is being held May 25-29 at ... won’t hear elsewhere about helpful interventions and causes of chronic illness in children. , ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
Breaking Medicine Technology: